JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

DexCom Inc

Fermé

SecteurSoins de santé

70.43 -0.84

Résumé

Variation du prix de l'action

24h

Actuel

Min

70.41

Max

71.17

Chiffres clés

By Trading Economics

Revenu

74M

180M

Ventes

121M

1.2B

P/E

Moyenne du Secteur

46.87

37.461

Marge bénéficiaire

15.539

Employés

10,200

EBITDA

90M

309M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+38.01% upside

Dividendes

By Dow Jones

Prochains Résultats

30 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-8.3B

27B

Ouverture précédente

71.27

Clôture précédente

70.43

Sentiment de l'Actualité

By Acuity

50%

50%

147 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

DexCom Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juil. 2025, 18:41 UTC

Acquisitions, Fusions, Rachats

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

Comparaison

Variation de prix

DexCom Inc prévision

Objectif de Prix

By TipRanks

38.01% hausse

Prévisions sur 12 Mois

Moyen 97.06 USD  38.01%

Haut 106 USD

Bas 85 USD

Basé sur 22 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

22 ratings

19

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

71.66 / N/ASupport & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

147 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat